InnoCare Pharma and Eli Lilly sign drug development deal worth up to $3.25 billion
InnoCare Pharma announced on September 24 that its wholly-owned subsidiary, Beijing InnoCare Pharma Tech, entered a research collaboration and exclusive license agreement with Eli Lilly. The partnership will leverage InnoCare's drug discovery platform to develop up to five novel target programs. Eli Lilly will pay up to $100 million in upfront and near-term payments, with potential milestone payments reaching approximately $3.25 billion, plus tiered single-digit royalties on net sales.
IllustrationEditorial responsibility
- No named human review is recorded for this page.
- Reports are grouped by semantic similarity and deterministic rules. Language models may assist titles, summaries, translation and cross-source analysis; the page reads the event directly, while its address stays stable when the title changes.
- Summary awaiting refresh
Summary awaiting refresh
Cross-source coverage
Reporting timeline
InnoCare Pharma Shares Surge After Unit Signs Licensing Deal with Eli Lilly Worth Up to $32.5 Billion
InnoCare Pharma's A-shares and H-shares rallied in afternoon trading on September 24 after the company announced that its wholly-owned subsidiary, Beijing InnoCare Pharma Tech Co., Ltd., signed a research collaboration and exclusive license agreement with Eli Lilly and Company. Under the deal, InnoCare will leverage its proprietary drug discovery platform to identify and develop up to five innovative target programs addressing significant unmet clinical needs. Eli Lilly will pay InnoCare up to $100 million in upfront and near-term milestone payments. Potential development and commercialization milestone payments total approximately $3.25 billion. Additionally, InnoCare is entitled to receive tiered, single-digit percentage royalties on annual net sales of licensed products. The news reversed an earlier decline of over 6% in A-shares and 5% in H-shares, with A-shares turning positive and H-shares narrowing losses to under 1%.
Read sourceInnoCare Pharma Shares Rise on Licensing Deal with Eli Lilly Worth Up to $3.25 Billion
InnoCare Pharma (HK: 9969, SH: 688428) saw its A-shares rise nearly 2% and H-shares turn positive in afternoon trading on March 18, 2025, following the announcement that its wholly-owned subsidiary has signed an exclusive licensing agreement with Eli Lilly. The deal includes milestone payments of up to $3.25 billion, though specific terms regarding the drug candidate or therapeutic area were not disclosed in the brief report. The stock movement reflects investor optimism about the potential value of the collaboration. The information was reported by Jin10 Data, a Chinese financial news service.
Read sourceInnoCare Pharma and Eli Lilly Enter Strategic Research Collaboration and License Agreement
InnoCare Pharma (09969) announced a strategic research collaboration and license agreement with global pharmaceutical leader Eli Lilly to develop new drugs. Under the agreement, InnoCare will use its proprietary drug development platform and extensive research experience to advance compounds targeting up to five targets, addressing unmet critical medical needs. InnoCare is eligible to receive up to $100 million in upfront and near-term payments, and up to approximately $3.25 billion in development and commercialization milestone payments, subject to applicable conditions and milestones. Additionally, InnoCare will receive tiered single-digit percentage royalties based on annual net product sales.
Read sourceShow 7 older updatesHide older updates
InnoCare Pharma and Eli Lilly Sign Drug Development Deal Worth Up to $3.25 Billion
InnoCare Pharma (688428.SH) announced that its wholly-owned subsidiary, Beijing InnoCare Pharma Tech Co., Ltd., has signed a research collaboration and license agreement with Eli Lilly and Company. The partnership focuses on strategic cooperation in innovative drug development, leveraging InnoCare's proprietary drug discovery platform to identify and develop up to five novel target projects addressing significant unmet clinical needs. Under the terms, Eli Lilly will pay InnoCare up to $100 million in upfront and near-term milestone payments. Potential total research, development, and commercialization milestone payments could reach approximately $3.25 billion, subject to specified conditions and milestones. Additionally, InnoCare is entitled to receive tiered, single-digit percentage royalties on annual net sales of licensed products. The company stated that the agreement supports its internationalization strategy and is expected to positively impact future performance.
Read sourceInnoCare Pharma and Eli Lilly Announce Strategic Research Collaboration and Licensing Agreement Worth Up to $3.25 Billion
InnoCare Pharma (09969.HK) announced on September 24 a strategic research collaboration and licensing agreement with global pharmaceutical leader Eli Lilly to develop new drugs. Under the agreement, InnoCare will use its proprietary drug development platform and extensive research experience to advance compounds targeting up to five disease targets, addressing critical unmet medical needs. InnoCare is eligible to receive up to $100 million in upfront and near-term payments, plus up to approximately $3.25 billion in development and commercialization milestone payments, subject to applicable conditions and milestones. Additionally, InnoCare will receive single-digit percentage tiered royalties based on annual net sales of products developed under the agreement.
Read sourceInnoCare Pharma Subsidiary Signs Licensing Deal with Eli Lilly Worth Up to $3.25 Billion in Milestones
InnoCare Pharma (诺诚健华) announced on September 24 that its wholly-owned subsidiary, Beijing InnoCare Pharma Tech, has entered into a research collaboration and licensing agreement with Eli Lilly and Company. The partnership focuses on strategic cooperation in innovative drug research and development, leveraging InnoCare's proprietary drug discovery platform to identify and develop up to five novel target projects addressing significant unmet clinical needs. Under the terms, Eli Lilly will pay InnoCare up to $100 million in upfront and near-term milestone payments. The total potential research, development, and commercialization milestone payments could reach approximately $3.25 billion. Additionally, InnoCare is entitled to receive tiered royalties at a single-digit percentage rate based on the annual net sales of licensed products.
Read sourceInnoCare Pharma Subsidiary Signs Licensing Deal with Eli Lilly Worth Up to $3.25 Billion
InnoCare Pharma announced on September 24 that its wholly-owned subsidiary, Beijing InnoCare Pharma Tech Co., Ltd., has entered into a research collaboration and exclusive license agreement with Eli Lilly and Company. The partnership focuses on strategic cooperation in innovative drug research and development, leveraging InnoCare's proprietary drug discovery platform to discover and develop up to five novel target projects addressing significant unmet clinical needs. Under the terms, Eli Lilly will pay InnoCare up to $100 million in upfront and near-term milestone payments. The total potential research, development, and commercialization milestone payments could reach approximately $3.25 billion, subject to the satisfaction of applicable conditions and milestones. Additionally, InnoCare is entitled to receive tiered, single-digit percentage royalties on annual net sales of licensed products.
Read sourceInnoCare Pharma Subsidiary Signs Licensing Deal with Eli Lilly, Up to $3.25 Billion in Milestones
InnoCare Pharma announced on September 24 that its wholly-owned subsidiary, Beijing InnoCare Pharma Tech Co., Ltd., has entered into a research collaboration and exclusive license agreement with Eli Lilly and Company. The partnership focuses on strategic cooperation in innovative drug development, leveraging InnoCare's proprietary drug discovery platform to identify and develop up to five novel target projects addressing significant unmet clinical needs. Under the terms, Eli Lilly will pay InnoCare up to $100 million in upfront and near-term milestone payments. Potential research, development, and commercialization milestone payments total approximately $3.25 billion. Additionally, InnoCare is entitled to receive tiered, single-digit percentage royalties on annual net sales of licensed products. The announcement was made via a stock exchange filing and reported by financial media outlet 格隆汇.
Read sourceInnoCare Pharma Subsidiary Signs Licensing Deal with Eli Lilly Worth Up to $3.25 Billion
InnoCare Pharma announced on September 24 that its wholly-owned subsidiary, Beijing InnoCare Pharma Tech Co., Ltd., has entered into a research collaboration and exclusive license agreement with Eli Lilly and Company. The partnership focuses on innovative drug discovery, leveraging InnoCare's proprietary drug discovery platform to develop up to five novel target programs addressing significant unmet clinical needs. Under the terms, Eli Lilly will pay InnoCare up to $100 million in upfront and near-term milestone payments. The total potential development and commercialization milestone payments could reach approximately $3.25 billion. Additionally, InnoCare is entitled to receive tiered royalties at a single-digit percentage rate on annual net sales of licensed products.
Read sourceInnoCare Pharma unit signs licensing deal with Eli Lilly worth up to $3.25 billion
InnoCare Pharma announced on September 24 that its wholly-owned subsidiary, Beijing InnoCare Pharma Tech, has entered into a research collaboration and licensing agreement with Eli Lilly and Company. The partnership focuses on strategic cooperation in innovative drug research and development, leveraging InnoCare's proprietary drug discovery platform to identify and develop up to five novel target projects addressing significant unmet clinical needs. Under the terms, Eli Lilly will pay InnoCare up to $100 million in upfront and near-term milestone payments. The total potential research, development, and commercialization milestone payments could reach approximately $3.25 billion. Additionally, InnoCare is entitled to receive tiered royalties at a single-digit percentage rate on annual net sales of licensed products.